Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$243 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.9
Industry P/E
--
EV/EBITDA
-2.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.3
Face value
--
Shares outstanding
45,127,800
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
TF Financial Corp (THRD)
| -47.7 | -1.3 | 4.5 | -55.6 | -- | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
|---|---|---|
|
TF Financial Corp (THRD)
| -6.1 | 155.1 |
|
S&P Small-Cap 600
| 7.0 | 13.9 |
|
BSE Sensex
| 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
TF Financial Corp (THRD)
|
5.4 | 242.8 | 0.1 | -53.5 | -138,120.8 | -18.8 | -- | 0.9 |
| 1.3 | 76.6 | 145.1 | -53.4 | -26.7 | -71.6 | -- | 0.8 |
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell... surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions. It has a license agreement with Novartis Pharma AG. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California. Read more
CEO & Director
Ms. Natalie C. Holles
CEO & Director
Ms. Natalie C. Holles
Headquarters
San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of TF Financial Corp (THRD) is $5.38 (NASDAQ) as of 12-Aug-2025 09:30 EDT. TF Financial Corp (THRD) has given a return of -55.61% in the last 1 years.
Since, TTM earnings of TF Financial Corp (THRD) is negative, P/E ratio is not available.
The P/B ratio of TF Financial Corp (THRD) is 0.89 times as on 13-Aug-2025, a 77 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
9.35
|
1.49
|
|
2023
|
-14.21
|
1.63
|
|
2022
|
-4.49
|
0.59
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of TF Financial Corp (THRD) are Rs 16.02 and Rs 3.18 as of 03-Apr-2026.
TF Financial Corp (THRD) has a market capitalisation of $ 243 Mln as on 13-Aug-2025. As per SEBI classification, it is a Small Cap company.
Before investing in TF Financial Corp (THRD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.